Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program

Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program

Background Avelumab, a human anti–programmed death-ligand 1 immunoglobulin G1 monoclonal antibody, showed favorable efficacy and safety in patients with metastatic Merkel cell carcinoma (mMCC) in the phase II JAVELIN Merkel 200 trial, leading to approval in multiple countries. We describe real-world...

Full description

Saved in:
Bibliographic Details
Main Authors: Celeste Lebbe, Paolo Antonio Ascierto, Shahneen Sandhu, Vijay Kasturi, Luc Dirix, Paul Nathan, Subramanian Hariharan, Giovanni Grignani, Eyal Fenig, Rodrigo Munhoz, Elena Benincasa, Sarah Flaskett, Josh Reed, Arne Engelsberg
Format: Article
Language:English
Published: BMJ Publishing Group 2020-05-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/8/1/e000313.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/8/1/e000313.full

Similar Items